Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04740242
Other study ID # ALCALOTIC
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 1, 2021
Est. completion date September 30, 2021

Study information

Verified date May 2022
Source Spanish Society of Internal Medicine
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Metabolic alkalosis (MA) is the most common acid-base disorder and when it's severe it can have effects on cellular function and contribute to an increase in mortality. MA is a common complication of heart failure (HF) especially when patients are treated with diuretics, but few studies have analyzed the prevalence of acid-base disorders in patients with HF. All these studies have shown that MA is more common in patients with HF in more advanced stages and that the use of diuretics increases the prevalence of MA. The study hypothesis, based on clinical experience and the few data that exist in the scientific literature, is that MA is a frequent analytical disorder in patients admitted for decompensated HF and that its presence entails a worse short-term vital prognosis. The ALCALOTIC study is an observational cohort and prospective study. The main objectives of the study are the following: 1. To determine the prevalence of MA in patients admitted for decompensated HF 2. To analyze if there are differences in patients admitted for HF according to the presence of MA on admission 3. To determine if the presence of MA has an influence on the short-term prognosis in patients admitted for decompensated HF


Recruitment information / eligibility

Status Completed
Enrollment 672
Est. completion date September 30, 2021
Est. primary completion date May 31, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patient admitted for decompensated HF (main admission diagnosis), who meet the diagnostic criteria of the 2016 European HF Guidelines and who sign the informed consent to participate in the study - Patients must give their written consent to participate in the study Exclusion Criteria: - Patients whose main reason for admission is not decompensated HF. Those patients who are admitted for another reason and who also have decompensated HF secondarily cannot be included - Patients who do not strictly meet the diagnostic criteria for HF of the European HF Guidelines. - Patients for whom analytical values are not available in relation to acid-base balance at the time of admission - Patients with a pathological history that can clearly justify metabolic alkalosis, such as primary or secondary hyperaldosterism - Patients who were taking sodium bicarbonate prior to admission - Patients with factors present at admission that may justify the presence of metabolis alkalosis: vomiting, diarrea, etc. - Patients who do not give their consent to participate in the study

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Spain Internal Medicine Service, Hospital d'Olot (Girona) Olot Girona

Sponsors (1)

Lead Sponsor Collaborator
Spanish Society of Internal Medicine

Country where clinical trial is conducted

Spain, 

References & Publications (2)

Galla JH. Metabolic alkalosis. J Am Soc Nephrol. 2000 Feb;11(2):369-375. doi: 10.1681/ASN.V112369. Review. — View Citation

Peixoto AJ, Alpern RJ. Treatment of severe metabolic alkalosis in a patient with congestive heart failure. Am J Kidney Dis. 2013 May;61(5):822-7. doi: 10.1053/j.ajkd.2012.10.028. Epub 2013 Mar 5. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary In-hospital mortality In-hospital mortality from all causes an average of 7 days
Secondary Mortality during follow-up All-cause mortality 30 and 90 days after hospital discharge Mortality at 30 and 90 days after hospital discharge
Secondary Re-admission (all cause) during follow-up Re-admission for all causes 30 and 90 days after hospital discharge Re-admission at 30 and 90 days after hospital discharge
Secondary Readmission for heart failure during follow-up Re-admission for heart failure 30 and 90 days after hospital discharge Readmission for heart failure 30 and 90 days after hospital discharge
Secondary Lenght of Hospital stay Lenght of Hospital stay during hospital admission Lenght of Hospital stay will be determined the day of hospital discharge, an average of 7 days after admission/inclusion
See also
  Status Clinical Trial Phase
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Recruiting NCT05196659 - Collaborative Quality Improvement (C-QIP) Study N/A
Recruiting NCT05654272 - Development of CIRC Technologies
Active, not recruiting NCT05896904 - Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction N/A
Completed NCT05077293 - Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
Recruiting NCT05631275 - The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
Enrolling by invitation NCT05564572 - Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology N/A
Enrolling by invitation NCT05009706 - Self-care in Older Frail Persons With Heart Failure Intervention N/A
Recruiting NCT04177199 - What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
Terminated NCT03615469 - Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY) N/A
Recruiting NCT06340048 - Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure Phase 1/Phase 2
Recruiting NCT05679713 - Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
Completed NCT04254328 - The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure N/A
Completed NCT03549169 - Decision Making for the Management the Symptoms in Adults of Heart Failure N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05538611 - Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
Recruiting NCT04262830 - Cancer Therapy Effects on the Heart
Completed NCT06026683 - Conduction System Stimulation to Avoid Left Ventricle Dysfunction N/A
Withdrawn NCT03091998 - Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support Phase 1
Recruiting NCT05564689 - Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy